SenesTech, Inc. develops a technology for managing animal pest populations by controlling fertility. The company is headquartered in Phoenix, Arizona.
82 articles
SenesTech CEO Michael Edell purchased 2,000 shares worth $1,740 as the stock trades near its 52-week low, amidst reports of record revenue but ongoing cash burn concerns.
SenesTech CEO Michael Edell discusses the company's unique rodent birth control niche and business model shifts toward e-commerce. He addresses recent stock underperformance, attributing it to early s
SenesTech CEO Michael Edell purchased 1,000 shares at $1.21 per share, increasing his direct ownership to 6,000 shares according to a Form 4 filing.
SenesTech Inc. announced it will present virtually at the Lytham Partners 2026 Consumer & Technology Investor Summit on August 18, highlighting its rodent birth control solutions like Evolve and Contr
SenesTech Inc reported a 2% overall revenue increase in Q1 2026 despite strong channel-specific growth, impacted by $443,000 in one-time operating expenses.
SenesTech Inc (SNES) holds an earnings forecast score of 8.00 within the Chemicals industry, with analysts projecting a $10.00 price target and negative EPS of -$0.41 for the next quarter.
Glenbrook Capital Management purchased 21,490 SenesTech shares at $1.297 per share, increasing its indirect holding to 1,079,294 shares without a Rule 10b5-1 plan.
SenesTech Inc is projected to report an earnings loss of 36 cents per share in its upcoming financial disclosure. This earnings preview aggregates expectations from sources such as Reuters via Trading
SenesTech Inc. reported Q2 2026 financial results with revenue increasing 23% year-over-year to $770K, driven primarily by its Evolve product. Despite a net loss of $1.83M, gross margins improved to 7
SenesTech reported narrower-than-expected losses and record revenue for Q2 2026, driven by strong e-commerce performance. Despite positive financial metrics, shares fell due to cash burn and lack of p
SenesTech reported Q2 2026 earnings with revenue up 23.2% to $770,000, surpassing analyst estimates. Diluted EPS narrowed to -$0.35, alongside notable insider stock purchases.
SenesTech reported Q2 2026 revenue up 23% to $770,000 driven by e-commerce, though net losses widened due to higher expenses. The company aims for profitability through sustained online growth and bet
SenesTech Inc reported record Q2 2026 revenue of $770,000, rising 56% sequentially, driven by e-commerce and agricultural B2B growth. Gross margins hit a record 73.6%.
SenesTech Inc. launched new assessment services for B2B clients to analyze rodent infestations and guide long-term management strategies. The offerings complement existing solutions like fertility con
SenesTech Inc will report Q2 2026 earnings on August 5, with estimated revenue of $0.6 million. GuruFocus forecasts a 74% downside despite analyst targets suggesting upside.
SenesTech reported a 186% surge in e-commerce revenue during Q2 2026, driven by doubling online subscription customers. The growth supports their subscription model for Evolve and ContraPest rodent bi
SenesTech reported its active online subscription customer base doubled in Q2 2026, with e-commerce revenue surging 186% driven by digital marketing and sales channel management for its Evolve and Con
SenesTech reported its active online subscriptions more than doubled in Q2 2026, driving an 186% quarter-over-quarter e-commerce growth. This supports recurring revenue for its Evolve and ContraPest r
SenesTech Inc. announced its active online subscription base more than doubled in Q2 2026 versus Q1, fueled by e-commerce investments. This growth strengthens their recurring revenue model for rodent
SenesTech Inc. will announce its Q2 2026 financial results after market close on August 5, 2026, with a concurrent conference call and webcast available via its Investor Relations website.
SenesTech Inc ranks 58th out of 65 in the Chemicals industry with a risk score of 2.26. The company exhibits lower volatility than the S&P 500 with a beta of 0.28.
SenesTech Inc (SNES) ranks 56th out of 65 in the Chemicals industry with a valuation score of 7.21 and a P/E ratio of -1.20. Additional financial ratios such as P/B and P/S have not yet been disclosed
Senestech Inc provides detailed quarterly and annual financial data on its balance sheet, enabling analysis of liquidity, leverage, and return on equity ratios.
SenesTech reported Q1 2026 financial results and expanded into Bermuda, noting the success of its Evolve Rodent Birth Control Solution.
SenesTech Inc. reported $2.22 million USD total revenue last year, primarily driven by its 'Evolve' segment originating from the United States.
SenesTech Inc presented a detailed financial overview for FY2025, covering stock performance, earnings data, and analyst ratings. The report includes comprehensive financial statements such as income,
Glenbrook Capital Management acquired a 19.95% activist stake in SenesTech, switching to Schedule 13D to influence strategy and operations while funding marketing initiatives.
Glenbrook Capital Management acquired a 19.95% stake in SenesTech for approximately $3.6 million, viewing the ag-biotech firm as undervalued and planning active engagement with its management.
SenesTech reports significant insider buying from 10% owner Glenbrook Capital, signaling confidence despite earnings misses. The company is undergoing strategic transformation with a new CEO focusing
Glenbrook Capital Management purchased 35,000 shares of SenesTech Inc. at $1.47/share, increasing indirect holdings to 1,057,824 shares.
ChemBrief